GoAI
Get started
Collegium Pharmaceutical, Inc. logo

Collegium Pharmaceutical, Inc.

COLL

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$27.11

−$0.43 · -1.56%

Aug 21, 4:00 PM ET

COLL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

98

Deep Value

Momentum

40

Weakening

Sentiment

60

Mixed

Risk resilience

56

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Vikram Karnani
Listed since
May 7, 2015
Employees
423

Market position

Day range

Current $27.11

52-week range

Current $27.11

Open
$27.56
Previous close
$27.54
Volume
704.93K
1.38× average
Average volume
509.51K
Average daily volume
Market cap
879.28M USD
Beta
0.76
Market reference 1
50-day average
$33.6344
-19.40% below average
200-day average
$38.9242
-30.35% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.16B USD
P/E (TTM)
17.72×
P/B (TTM)
2.82×
P/S (TTM)
1.09×
EV / EBITDA
5.38×
Earnings yield
4.28%
Free cash flow yield
22.31%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
60.02%
Operating margin
19.61%
Net margin
5.93%
Return on equity
20.84%
Return on assets
3.79%
Return on invested capital
10.18%

Financial health

Debt / equity
2.75×
Current ratio
1.57×
Altman Z-score
0.98
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends66%40%14%-12%Gross margin, FY2021: 54.40%Gross margin, FY2022: 45.15%Gross margin, FY2023: 57.55%Gross margin, FY2024: 59.76%Gross margin, FY2025: 59.35%Operating margin, FY2021: 6.37%Operating margin, FY2022: 7.18%Operating margin, FY2023: 29.46%Operating margin, FY2024: 26.91%Operating margin, FY2025: 23.97%Net margin, FY2021: 25.83%Net margin, FY2022: -5.39%Net margin, FY2023: 8.50%Net margin, FY2024: 10.96%Net margin, FY2025: 8.05%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 54.40%. Gross margin FY2022 45.15%. Gross margin FY2023 57.55%. Gross margin FY2024 59.76%. Gross margin FY2025 59.35%. Operating margin FY2021 6.37%. Operating margin FY2022 7.18%. Operating margin FY2023 29.46%. Operating margin FY2024 26.91%. Operating margin FY2025 23.97%. Net margin FY2021 25.83%. Net margin FY2022 -5.39%. Net margin FY2023 8.50%. Net margin FY2024 10.96%. Net margin FY2025 8.05%.

Income trends

Revenue

780.57M USD+23.62%

Operating income

187.08M USD+10.12%

Net income

62.87M USD-9.13%
Income trends across reported periods861.12M USD538.9M USD216.67M USD−105.56M USDRevenue, FY2021: 276.87M USDRevenue, FY2022: 463.93M USDRevenue, FY2023: 566.77M USDRevenue, FY2024: 631.45M USDRevenue, FY2025: 780.57M USDOperating income, FY2021: 17.63M USDOperating income, FY2022: 33.32M USDOperating income, FY2023: 166.96M USDOperating income, FY2024: 169.9M USDOperating income, FY2025: 187.08M USDNet income, FY2021: 71.52M USDNet income, FY2022: −25M USDNet income, FY2023: 48.16M USDNet income, FY2024: 69.19M USDNet income, FY2025: 62.87M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 276.87M USD. Revenue FY2022 463.93M USD. Revenue FY2023 566.77M USD. Revenue FY2024 631.45M USD. Revenue FY2025 780.57M USD. Operating income FY2021 17.63M USD. Operating income FY2022 33.32M USD. Operating income FY2023 166.96M USD. Operating income FY2024 169.9M USD. Operating income FY2025 187.08M USD. Net income FY2021 71.52M USD. Net income FY2022 −25M USD. Net income FY2023 48.16M USD. Net income FY2024 69.19M USD. Net income FY2025 62.87M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue780.57M USD631.45M USD566.77M USD463.93M USD276.87M USD
Cost of goods sold317.31M USD254.11M USD240.6M USD254.45M USD126.25M USD
Gross profit463.26M USD377.34M USD326.17M USD209.49M USD150.62M USD
Research and development———3.98M USD9.45M USD
Selling, general, and administrative276.17M USD182.98M USD159.21M USD172.19M USD118.96M USD
Operating expenses276.17M USD207.45M USD159.21M USD176.17M USD132.99M USD
Interest income11.29M USD13.98M USD15.62M USD1.05M USD12K USD
Interest expense82.31M USD73.97M USD83.34M USD63.21M USD21.01M USD
Depreciation and amortization226.07M USD169.16M USD149.26M USD138.94M USD68.92M USD
Operating income187.08M USD169.9M USD166.96M USD33.32M USD17.63M USD
Net income62.87M USD69.19M USD48.16M USD−25M USD71.52M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+8.15%
11 comparable reports
Latest EPS result
1.92
Estimate 1.72 · Beat by 11.63%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.342.011.671.34Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 1.77, estimate 1.54, surprise +14.94%, Beat. Q2 2025, reported May 8, 2025: actual 1.49, estimate 1.43, surprise +4.20%, Beat. Q3 2025, reported Aug 7, 2025: actual 1.68, estimate 1.62, surprise +3.70%, Beat. Q4 2025, reported Nov 6, 2025: actual 2.25, estimate 1.86, surprise +20.97%, Beat. Q1 2026, reported Feb 26, 2026: actual 2.04, estimate 2.14, surprise -4.67%, Miss. Q2 2026, reported May 7, 2026: actual 1.76, estimate 1.52, surprise +15.79%, Beat. Q3 2026, reported Aug 6, 2026: actual 1.92, estimate 1.72, surprise +11.63%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.86, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates227.21M206.26M185.3M164.34MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 181.95M USD, estimate 179.68M USD, surprise +1.26%, Beat. Q2 2025, reported May 8, 2025: actual 177.76M USD, estimate 173.08M USD, surprise +2.70%, Beat. Q3 2025, reported Aug 7, 2025: actual 188M USD, estimate 191.31M USD, surprise -1.73%, Miss. Q4 2025, reported Nov 6, 2025: actual 209.36M USD, estimate 206.16M USD, surprise +1.55%, Beat. Q1 2026, reported Feb 26, 2026: actual 205.45M USD, estimate 206.36M USD, surprise -0.44%, Miss. Q2 2026, reported May 7, 2026: actual 193.52M USD, estimate 184.47M USD, surprise +4.91%, Beat. Q3 2026, reported Aug 6, 2026: actual 199.88M USD, estimate 199.63M USD, surprise +0.13%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 218.48M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$48.00

77.06% upside
Past 12 months12-month forecastHigh $48.00Average $48.00Low $48.00

COLL news

globenewswire.com

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood…

Read source
defenseworld.net

Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey

Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Avenue Therapeutics (NASDAQ: ATXI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…

Read source
seekingalpha.com

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street…

Read source
zacks.com

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.

Read source
marketbeat.com

Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the…

Read source

COLL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding COLL

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
55.43M
Weight
0.05%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
34.61M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
23.24M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
13.18M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
11.44M
Weight
0.04%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Invesco Pharmaceuticals ETF logoInvesco Pharmaceuticals ETFPJP
Market value
10.62M
Weight
2.01%
AUM
535.56M USD
Expense ratio
0.57%
Price / 1D
$130.06+0.91%
iShares S&P Small-Cap 600 Growth ETF logoiShares S&P Small-Cap 600 Growth ETFIJT
Market value
8.4M
Weight
0.10%
AUM
8.22B USD
Expense ratio
0.18%
Price / 1D
$173.9+0.61%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
8.37M
Weight
0.06%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%

Continue in GoAI

Research COLL

research.disclaimer